- Home
- STTK vs SACH Comparison
STTK vs SACH Comparison
Compare STTK & SACH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- SACH
- Stock Information
- Founded
- STTK 2016
- SACH 2010
- Country
- STTK United States
- SACH United States
- Employees
- STTK 44
- SACH N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- SACH Real Estate Investment Trusts
- Sector
- STTK Health Care
- SACH Real Estate
- Exchange
- STTK Nasdaq
- SACH Nasdaq
- Market Cap
- STTK 48.9M
- SACH 53.5M
- IPO Year
- STTK 2020
- SACH 2017
- Fundamental
- Price
- STTK $1.02
- SACH $1.16
- Analyst Decision
- STTK Hold
- SACH Hold
- Analyst Count
- STTK 5
- SACH 4
- Target Price
- STTK $2.00
- SACH $2.25
- AVG Volume (30 Days)
- STTK 5.2M
- SACH 123.6K
- Earning Date
- STTK 08-14-2025
- SACH 08-05-2025
- Dividend Yield
- STTK N/A
- SACH 17.39%
- EPS Growth
- STTK N/A
- SACH N/A
- EPS
- STTK N/A
- SACH N/A
- Revenue
- STTK $2,997,000.00
- SACH N/A
- Revenue This Year
- STTK N/A
- SACH N/A
- Revenue Next Year
- STTK N/A
- SACH $4.98
- P/E Ratio
- STTK N/A
- SACH N/A
- Revenue Growth
- STTK N/A
- SACH N/A
- 52 Week Low
- STTK $0.69
- SACH $0.80
- 52 Week High
- STTK $3.95
- SACH $2.70
- Technical
- Relative Strength Index (RSI)
- STTK 61.64
- SACH 50.49
- Support Level
- STTK $0.71
- SACH $1.10
- Resistance Level
- STTK $1.05
- SACH $1.18
- Average True Range (ATR)
- STTK 0.09
- SACH 0.04
- MACD
- STTK 0.03
- SACH -0.00
- Stochastic Oscillator
- STTK 69.18
- SACH 54.55
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About SACH Sachem Capital Corp.
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.